Montana has established a new review board allowing biotech companies to sell experimental drugs that have undergone only preliminary testing.

Montana has launched a new regulatory framework allowing biotech companies to apply for approval to sell experimental drugs that have completed only preliminary testing. Under the new rules, companies can pay a $12,500 fee to submit their treatments to a state-established review board. Once approved, these drugs can be sold through experimental treatment clinics, with the first of these facilities expected to begin operations by the end of this year.

Regulatory Framework and Access

The legislation allows for the sale of drugs that may have been tested on as few as 10 healthy individuals. Access to these treatments is available to any individual who provides informed consent and possesses the financial means to pay for the therapy. While proponents in the longevity community view this as a hopeful development, critics have raised concerns regarding the ethics and safety of the policy.

Patient Perspectives on Experimental Treatments

The policy has drawn attention from families seeking treatments for rare conditions. One case involves a child named Brody, born in March 2023, who suffers from creatine transporter deficiency, a condition characterized by the brain and muscles lacking necessary energy. Although no cure exists, his family is pursuing access to an experimental drug currently in early development that has only been tested in animals and a small group of healthy adults.